Several bacterial genera, notably the spirochaetes (Lyme disease and syphilis) and the mycobacteria, can cause very slowly evolving infections with characteristically varied presentation and complex evolution. These features are due in part to unexplained tropisms which localise the infection in certain sites, and in part to the 'spectrum' of immune responses which they can evoke. This can be dominated by T When the T cell mediated response is prominent in a slow bacterial infection, autoantibody formation can be less striking, and the disease process generates T cell dependent granulomata with variable degrees of central necrosis. This necrosis is seen in tuberculosis and in the gumma of tertiary syphilis, and overlap with the histological appearance of rheumatoid skin nodules has often been noted. However, necrosis is not a feature of infections due to Mycobacterium intracellulare and M malmoense in the cervical lymph nodes of children, and the histology of these infections more closely resembles that of sarcoidosis.
Slow bacterial infections have a predilection for the lungs (tuberculosis), skin (leprosy, M ulcerans, M marinum), and gut. The ability of mycobacteria to infect the gut deserves further emphasis. Some variants of M avium (mycobactin dependent), including the organism known as M paratuberculosis, cause a chronic granulomatous intestinal infection in cattle, goats, and deer, and recently a similar disease has been described in monkeys.' With loss of CD4 T cells in HIV infected persons, a limited number of serotypes of mycobactin independent M avium can cause similar appearances in the human intestine.2 Such infections with conventional mycobacteria are in many ways similar to the inflammatory bowel disease spectrum.3 In fact sarcoidosis, Crohn's disease, and RA tend, like the established slow bacterial infections, to affect the lungs, skin, and gut. Thus although Crohn's disease is an inflammatory bowel disease, the lung lavages of these patients are grossly abnormal,4 and lung damage is a serious complication in some cases of RA. 5 Similarly, there is evidence for gut abnormalities in sarcoidosis6 and RA,7 and arthritis can occur in all of these conditions.8 9 It should be stressed that this pattern of disease is quite unlike that seen in the organ specific disorders of proved autoimmune aetiology ( antigens that are confined to the mycobacteria, and to a very closely related genus, are also found in rheumatoid joints (see below).
Epidemiology
The epidemiology of sarcoidosis and Crohn's disease points to an environmental factor,27-29 likely to be an infection, because there is well documented clustering in space and time, and geographical variation independent of race. The epidemiology of RA is less obvious, though studies of fossil evidence suggest that it is a recent disease, which has behaved like an, epidemic in the West, but has now reached a peak and may even be declining. Meanwhile and can be found in the peripheral blood of normal donors.39 Moreover, there is now some doubt about the validity of at least some work on T cell reactivity to collagen because the pepsin used to prepare it is a potent T cell stimulus and has been shown to account for much of the apparent reactivity in both murine and human studies. 40 The possibility that there is autoreactivity to heat shock proteins (hsps) is more difficult to analyse. There is concrete proof that sequences derived from the mycobacterial 65 kilodalton hsp are relevant to most, perhaps all, the rodent models of arthritis,4'-44 so it was logical to seek evidence for responses to this protein in human disease. The data on this point are conflicting, as discussed later, but most authors agree that there are at least some T cells responding to mycobacterial hsp65 in rheumatoid joints. Do any of these T cells also recognise the human homologue, which is the 60 kilodalton mitochondrial hsp? There are reports that some T cells from reactive arthritis and from juvenile chronic arthritis do indeed have this property, though the frequency of such cells is not clear. 45 When the epitopes recognised by other clones responding to the mycobacterial hsp65 were studied they turned out to be sequences with only limited homology to the human protein. 46 These clones will respond to the corresponding human sequence, but only when this is present at high concentrations. At first sight this seems to imply that this cross reactivity is irrelevant, but recent findings in a quite different model suggest that this conclusion may be premature. A study of the sequence from myelin basic protein, which is involved in the pathogenesis of experimental autoallergic encephalitis in mice, has shown that the peptide causing disease has a remarkably low affinity for the major histocompatibility complex (MHC (fig 1) . The %Gal(0) correlates closely with disease activity in RA, and if assayed early in disease, with prognosis. 72 The importance of Gal(0) in the present context is that very high 0/oGal(O) is seen not only in RA but also in tuberculosis, leprosy (particularly with erythema nodosum leprosum),73 and in inflammatory bowel diseases74 and a subset of sarcoidosis.75 It does not appear to rise in virus infections, or after major surgery, or in a variety of other autoimmune disorders and inflammatory conditions,72 including acute rheumatic fever. 76 How is %/oGal(0) regulated? There is indirect, but strong evidence that interleukin 6 (IL-6) has a role. Firstly, levels of Gal(0) were extremely high in transgenic mice overexpressing the human IL-6 gene,77 and they rise after direct injection of recombinant IL-6 into the peritoneal cavities of normal DBA/1 mice. 78 Moreover, levels of IL-6 correlate with %Gal(0) in mice injected with pristane,78 and in patients with Castleman's disease, or IL-6 secreting tumours (cardiac myxomata and carcinoma of the cervix),79 and in the subset of patients with sarcoidosis who have raised %Gal(0) (Rook, O'Connor, et al, unpublished observation). These correlations are supported by the observation that IL-6 causes changes in the activity of galactosyltransferase in B cells,80 and it is not surprising to find that the most strikingly raised cytokine in rheumatoid joints is IL-6, which seems to be released spontaneously in vitro by cells derived from such joints.81
As IL-6 is a cytokine released nonspecifically in most inflammatory conditions, is it logical to suggest that a raised %Gal (0) Animal models Superficially the animal models of arthritis do not appear to involve infection as they are evoked without injecting live organisms. Some authors consider these models to be unrelated to the human disorders, but they are accompanied by raised responses to hsp65 and by raised %Gal(O).43 82 We regard these areas of overlap with human disease as particularly meaningful. Another striking feature of the rodent models is the influence of unknown environmental factors. This has been observed in MRL mice, in the pristane arthritis model, and in collagen arthritis. In each of these models the incidence of arthritis seems to be influenced by whether the animals are bred under specific pathogen free conditions or not, and by the general cleanliness of the facilities. 87 It is particularly interesting that DBA/1 mice from a 'clean' commercial supplier develop little arthritis after intraperitoneal pristane if they are kept in an isolator. The good evidence for relevant autoreactive T cells in RA. (5) Altered antibody and skin test responses to mycobacteria in RA. The skin test changes correlate with DR4 in RA59 and leprosy60 but not in normal subjects. (6) Responses to the mycobacterial 65 kilodalton hsp in most, perhaps all, the rodent models of arthritis, together with evidence that environmental microorganisms also have a crucial role in these models. Figure 2 illustrates these and other arguments combined in the hypothesis. The arrival of recombinant DNA technology means that the role of infections in RA, inflammatory bowel diseases, and sarcoidosis will be established or refuted within the next few years. If the infection hypothesis proves to be correct the treatment of RA will need to be completely revised, and the consequences for the pharmaceutical industry will be enormous. It could become unethical to use steroids, or agents which block prostaglandin synthesis, as we cannot be sure that they do not promote proliferation of the organism, and so in the long term lead to more severe disease. Instead we will need to devise antibiotic regimens and immunotherapeutic protocols.
We would like to thank Dr J McCulloch for his critical reading of the manuscript. 
